The brief

Analyst view

• Conditional approval in Japan (Feb 2026) for ReHeart, world's first iPSC cardiomyocyte sheet therapy for ischemic heart failure.
• Investigator trial of eight patients: all showed improvement, no adverse events; commercial launch planned autumn 2026.
• Targets severe ischemic heart failure patients who have exhausted conventional treatment options or surgery.

Technical approach

As reported

Cell sheet design

Thin cardiomyocyte patch

ReHeart is a 4–5 cm diameter, 0.1 mm thick sheet of iPSC-derived heart muscle cells that can be applied directly to the surface of the heart.

Cell source

Donor-derived iPSCs

Cardiomyocytes are differentiated from donor iPSCs, which can develop into nearly all tissue types and offer a renewable cell source.

Integration

Repair and electrical function

The transplanted sheet integrates with host heart tissue, restoring myocardial function and electrical conductivity to improve cardiac output.